Unity Biotechnology, Inc.
Unity Biotechnology, Inc. (0YC0.L) Stock Overview
Explore Unity Biotechnology, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
4M
P/E Ratio
-0.12
EPS (TTM)
$-1.08
ROE
-2.74%
0YC0.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Unity Biotechnology, Inc. (0YC0.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 18.48, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.56.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.12 and a market capitalization of 4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Anirvan Ghosh
16
285 East Grand Avenue, South San Francisco, CA
2018